Domenici Alessandro, Giuliani Anna
Department of Clinical and Molecular Medicine, "Sapienza" University, Sant'Andrea Hospital, Nephrology and Dialysis Unit, Rome, Italy.
Department of Nephrology Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy.
Int J Nephrol Renovasc Dis. 2021 Oct 7;14:385-392. doi: 10.2147/IJNRD.S236553. eCollection 2021.
A steadily increasing number of end stage kidney disease (ESKD) patients are maintained on automated peritoneal dialysis (APD) worldwide, in long-standing as well as in more recently established peritoneal dialysis (PD) programs. A better understanding of the technique, paralleled by progress in involved technology, sustained this growth to the point that APD has become the prevalent mode of PD delivery in most high-income countries. While APD is now regarded to be at least as efficient as continuous ambulatory peritoneal dialysis (CAPD) with regard to major biomedical outcomes, its impact on patient-reported outcomes has been less investigated. This paper reviews the main outcomes of APD from a clinical point of view and from the person on dialysis perspective.
在全球范围内，无论是在长期存在的还是最近建立的腹膜透析（PD）项目中，接受自动腹膜透析（APD）治疗的终末期肾病（ESKD）患者数量都在稳步增加。对该技术的深入理解，再加上相关技术的进步，推动了这一增长，以至于在大多数高收入国家，APD已成为PD治疗的主要方式。虽然就主要生物医学结果而言，现在认为APD至少与持续性非卧床腹膜透析（CAPD）一样有效，但其对患者报告结果的影响却较少得到研究。本文从临床角度以及透析患者的角度回顾了APD的主要结果。
